Low-dose naltrexone is hypothesized to alleviate PASC symptoms through neuroinflammation modulation by antagonizing toll-like receptors 4 on microglia and macrophages, leading to reduced production of pro-inflammatory cytokines (e.g., IL-6, TNF-alpha) and oxidative stress [28, 29]. Here, IL6 is linked to long COVID-19.